.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Covington
Julphar
Accenture
Cantor Fitzgerald
Moodys
Queensland Health
Express Scripts
Merck

Generated: December 18, 2017

DrugPatentWatch Database Preview

Vanda Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for VANDA PHARMS INC, and what generic alternatives to VANDA PHARMS INC drugs are available?

VANDA PHARMS INC has two approved drugs.

There are sixteen US patents protecting VANDA PHARMS INC drugs.

There are two hundred and fifty-nine patent family members on VANDA PHARMS INC drugs in thirty-nine countries.

Summary for Vanda Pharms Inc

International Patents:259
US Patents:16
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-001May 6, 2009ABRXYesYes► Subscribe► SubscribeYY► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-002May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-006May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-004May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-002May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-007May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-001May 6, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Vanda Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-005May 6, 2009► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-007May 6, 2009► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-004May 6, 2009► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-001May 6, 2009► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-006May 6, 2009► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-003May 6, 2009► Subscribe► Subscribe
Vanda Pharms IncFANAPTiloperidoneTABLET;ORAL022192-002May 6, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for VANDA PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
iloperidoneTablets1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, & 12 mgFANAPT5/6/2013

Non-Orange Book Patents for Vanda Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,207,680 Heteroarylpiperidines and their use as antipsychotics and analgesics► Subscribe
5,614,543 1-(aryloxyalkyl)-3- (heteroaryl) pyrrolidines and related compounds useful as antipsychotics and analgesics► Subscribe
5,578,624 Heteroarylpyrrolidines and their use as antipsychotics and analgesics► Subscribe
5,612,343 N-[(4-heteroaryl-1-piperazinyl)alkyl]-2,3-naphthalimides and related compounds and their therapeutic utility► Subscribe
5,637,710 Intermediate compounds in the synthesis of heteroarylpiperidines and piperazines► Subscribe
5,550,130 1-[(1,4-benzodioxanyl)alkyl]-4-(heteroaryl)piperidines and related compounds and their therapeutic utility► Subscribe
RE37478 1-(arylthioalkyl, arylaminoalkyl, or arylmethylenealkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics► Subscribe
5,561,128 N-[(4-(hete roaryl)-1-piperidinyl)alkyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility► Subscribe
5,589,494 2-[(3-heteroaryl-1-pyrrolidinyl)alkyl]-1,3-dioxanes and related compounds and their therapeutic utility► Subscribe
5,624,927 N-[4-(heteroaryl)-1-piperazinyl)alkyl]-1,2,3,4-tetrahydroisoquinolines and n-[4(heteroaryl)-1-piperazinyl)alkyl]-1,2,3,4-tetrahydroisoquinolines, related compounds and their therapeutic utility► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Vanda Pharms Inc Drugs

Country Document Number Estimated Expiration
Poland181059► Subscribe
Slovakia242590► Subscribe
World Intellectual Property Organization (WIPO)2013112949► Subscribe
Russian Federation2190609► Subscribe
Canada2757713► Subscribe
World Intellectual Property Organization (WIPO)2008121899► Subscribe
Poland176230► Subscribe
Australia8122894► Subscribe
Poland163965► Subscribe
Canada2121253► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
McKesson
AstraZeneca
Queensland Health
Cantor Fitzgerald
Covington
Colorcon
Baxter
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot